liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs
University of Utrecht, Netherlands .
Erasmus University, Netherlands .
University of Utrecht, Netherlands .
University of Utrecht, Netherlands .
Show others and affiliations
2012 (English)In: Pharmacogenomics (London), ISSN 1462-2416, E-ISSN 1744-8042, Vol. 13, no 12, 1405-1417 p.Article, review/survey (Refereed) Published
Abstract [en]

Genotyping patients for CYP2C9 and VKORC1 polymorphisms can improve the accuracy of dosing during the initiation of anticoagulation with vitamin K antagonists (coumarin derivatives). The anticipated degree of improvement in the safety of anticoagulation with coumarins through genotyping may vary depending on the quality of patient care, which varies both with and among countries. The management and the cost of anticoagulant care can therefore influence the cost effectiveness of genotyping within any given country. In this article, we provide an overview of the cost effectiveness of pharmacogenetics-guided dosing of coumarin derivatives. We describe the organization of anticoagulant care in the UK, Sweden, The Netherlands, Greece, Germany and Austria, where a genotype-guided dosing algorithm is currently being investigated as part of the EU-PACT trial. We also explore the costs of anticoagulant care for the treatment of atrial fibrillation in these countries.

Place, publisher, year, edition, pages
Future Medicine , 2012. Vol. 13, no 12, 1405-1417 p.
Keyword [en]
acenocoumarol, atrial fibrillation, cost analysis, coumarins, health, economics, healthcare system, phenprocoumon, warfarin
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-84904DOI: 10.2217/PGS.12.124ISI: 000308776100016OAI: diva2:562915

Funding Agencies|EU|HEALTH-F2-2009-223062|Netherlands Organisation for Health Research and Development (ZonMW)||Dutch Health Care Insurance Board (CVZ)||Royal Dutch Pharmacists Association (KNMP)||private public funded Top Institute Pharma||EU Innovative Medicines Initiative (IMI)||FP7||Dutch Medicines Evaluation Board||Dutch Ministry of Health and industry||

Available from: 2012-10-26 Created: 2012-10-26 Last updated: 2012-10-26

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Levin, Lars-Åke
By organisation
Health Technology Assessment and Health EconomicsFaculty of Health Sciences
In the same journal
Pharmacogenomics (London)
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 54 hits
ReferencesLink to record
Permanent link

Direct link